CTLA4 and neoplasm: Antibodies to T cell checkpoint proteins CTLA-4, PD-1, and PD-L1 have resulted in durable clinical responses for some cancer patients, but many patients do not respond [52, 53], suggesting that overcoming additional immunosuppressive mechanisms will be necessary to reactivate anti-tumor immunity in resistant patients.